Merck & Co., Inc. (NYSE:MRK) EVP Sells $14,485,422.95 in Stock

Merck & Co., Inc. (NYSE:MRK) EVP Jennifer Zachary sold 121,573 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the transaction, the executive vice president owned 68,916 shares in the company, valued at $8,211,341.40. This trade represents a 63.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Merck & Co., Inc. Stock Performance

Shares of MRK stock traded down $4.26 on Monday, hitting $117.67. 16,007,310 shares of the stock traded hands, compared to its average volume of 14,144,574. The company’s fifty day moving average is $106.58 and its 200 day moving average is $93.29. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $122.66. The company has a market capitalization of $292.06 billion, a PE ratio of 16.16, a PEG ratio of 2.28 and a beta of 0.28. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.66 and a quick ratio of 1.44.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 45.22% and a net margin of 28.08%.The business had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter last year, the business posted $1.72 EPS. The business’s revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s payout ratio is presently 46.70%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Keytruda patent protection extended to late‑2029 and strategic execution could unlock near‑term cash and boost longer‑term value—analyst note calls MRK a “buy” for 2026 and forecasts material upside from QLEX migration and other levers. Merck: A Buy For 2026, But The Clock Is Still Ticking
• Positive Sentiment: Bull case argues the recent price surge isn’t excessive given a diverse portfolio, new approvals (QLEX), strong vaccine performance (Capvaxive up ~460%), and ongoing pipeline innovation to offset future Keytruda erosion. Merck: The Spike Doesn’t Make It Overvalued
• Positive Sentiment: Recent analyst upgrade has already supported an earlier price uptick, reflecting renewed investor enthusiasm around growth and dividend attractiveness. Merck & Co., Inc. (NYSE:MRK) Stock Price Up 1.8% After Analyst Upgrade
• Positive Sentiment: Investment write‑ups highlight Merck as a Dow Dividend candidate for long‑term income investors, reinforcing buy‑and‑hold demand for dividend strategies. 3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026
• Neutral Sentiment: Longer-form bull case pieces are circulating that recap upside scenarios and risks; useful for context but not a single catalytic item. Merck Co., Inc. (MRK): A bull case theory
• Negative Sentiment: Street sentiment cooled with a recent downgrade, which can pressure momentum investors and reduce near‑term upside. From Bargain To Balancing Act: Merck’s Next Test Begins (Rating Downgrade)
• Negative Sentiment: Several high‑profile insider sales (CFO, EVP and other executives) totaling multi‑million dollars were reported over the last 48 hours; large insider dispositions often raise short‑term concern about insider conviction. Merck & Co., Inc. (NYSE:MRK) CFO Sells $5,023,261.17 in Stock Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells $4,556,870.20 in Stock Dean Li Sells 15,087 Shares of Merck & Co., Inc.
• Negative Sentiment: Another boutique outlet lowered its rating, adding to the mix of caution from some analysts and possibly amplifying volatility. Merck & Co., Inc. (NYSE:MRK) Stock Rating Lowered by Wall Street Zen

Wall Street Analysts Forecast Growth

MRK has been the subject of several recent research reports. The Goldman Sachs Group boosted their price target on Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Merck & Co., Inc. from $110.00 to $111.00 and gave the company a “hold” rating in a research note on Tuesday, November 18th. Scotiabank increased their target price on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a research report on Thursday, December 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Merck & Co., Inc. in a research note on Monday, December 29th. Finally, UBS Group raised their price objective on Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $119.53.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Brighton Jones LLC boosted its position in Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after buying an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Merck & Co., Inc. by 52.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after acquiring an additional 3,941 shares in the last quarter. Richardson Financial Services Inc. grew its position in Merck & Co., Inc. by 26.1% during the 2nd quarter. Richardson Financial Services Inc. now owns 893 shares of the company’s stock worth $73,000 after acquiring an additional 185 shares during the last quarter. GFS Advisors LLC increased its holdings in Merck & Co., Inc. by 60.0% during the 2nd quarter. GFS Advisors LLC now owns 131,814 shares of the company’s stock valued at $10,434,000 after purchasing an additional 49,440 shares in the last quarter. Finally, Inman Jager Wealth Management LLC raised its position in Merck & Co., Inc. by 11.7% in the 2nd quarter. Inman Jager Wealth Management LLC now owns 17,272 shares of the company’s stock valued at $1,367,000 after purchasing an additional 1,811 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.